Claims

1. Use of a population of allogeneic T cells for the manufacture of a medicament for the treatment of an EBV-LPD (Epstein-Barr Virus-associated lymphoproliferative disorder) in a human patient, wherein the human patient has failed a combination chemotherapy to treat the EBV-LPD, and wherein the population of allogeneic T cells comprises EBV-specific T cells and is restricted by an human leukocyte antigen (HLA) allele shared with cells of the EBV-LPD.
2. The use of claim 1, wherein the EBV-LPD is resistant to the combination chemotherapy to treat the EBV-LPD.
3. The use of claim 1 or 2, wherein the human patient has failed multiple different combination chemotherapies to treat the EBV-LPD.
4. The use of claim 3, wherein the EBV-LPD is resistant to the multiple different combination chemotherapies to treat the EBV-LPD.
5. The use of any of claims 1-4, wherein the human patient also has failed a radiation therapy to treat the EBV-LPD.
6. The use of claim 5, wherein the EBV-LPD is resistant to the radiation therapy to treat the EBV-LPD.
7. Use of a population of allogeneic T cells for the manufacture of a medicament for the treatment of an EBV-LPD in a human patient, wherein the human patient has failed a radiation therapy to treat the EBV-LPD, and wherein the population of allogeneic T cells comprises EBV-specific T cells and is restricted by an HLA allele shared with cells of the EBV-LPD.
8. The use of claim 7, wherein the EBV-LPD is resistant to the radiation therapy to treat the EBV-LPD.
9. The use of any of claims 1-8, wherein the EBV-LPD is a disorder of cells of B cell lineage and the human patient also has failed a therapy with an anti-CD20 monoclonal antibody to treat the EBV-LPD.
10. The use of claim 9, wherein the EBV-LPD is resistant to the therapy with the anti-CD20 monoclonal antibody to treat the EBV-LPD.
11. The use of claim 9 or 10, wherein the anti-CD20 monoclonal antibody is rituximab.

12. The use of any of claims 1-11, wherein the EBV-LPD is an EBV-positive lymphoma.
13. The use of any of claims 1-11, wherein the EBV-LPD is diffuse large B-cell lymphoma.
14. The use of any of claims 1-13, wherein the EBV-LPD is present in the central nervous system of the human patient.
15. The use of claim 14, wherein the EBV-LPD is present in the brain of the human patient.
16. The use of any of claims 1-15, wherein the human patient has been the recipient of a solid organ transplant from a transplant donor.
17. The use of any of claims 1-15, wherein the human patient has been the recipient of a hematopoietic stem cell transplant from a transplant donor.
18. The use of claim 16 or 17, wherein the population of allogeneic T cells is derived from a donor other than the transplant donor.
19. The use of any of claims 1-15, wherein the human patient is infected with HIV.
20. The use of any of claims 1-19, wherein the treatment is a method comprising, after administering to the human patient the population of allogeneic T cells, administering to the human patient a second population of allogeneic T cells comprising EBV-specific T cells; wherein the second population of allogeneic T cells is restricted by a different HLA allele shared with cells of the EBV-LPD.